Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uveitis | 72 | 2024 | 396 | 11.760 |
Why?
|
Visual Acuity | 62 | 2024 | 2672 | 3.380 |
Why?
|
Cataract | 28 | 2024 | 831 | 3.370 |
Why?
|
Cytomegalovirus Retinitis | 22 | 2020 | 56 | 3.340 |
Why?
|
Scleritis | 16 | 2021 | 96 | 3.180 |
Why?
|
Uveitis, Anterior | 15 | 2023 | 101 | 3.120 |
Why?
|
AIDS-Related Opportunistic Infections | 18 | 2020 | 662 | 2.920 |
Why?
|
Panuveitis | 11 | 2023 | 33 | 2.880 |
Why?
|
Uveitis, Intermediate | 9 | 2021 | 17 | 2.790 |
Why?
|
Glucocorticoids | 35 | 2023 | 2160 | 2.620 |
Why?
|
Fluocinolone Acetonide | 15 | 2020 | 38 | 2.570 |
Why?
|
Cataract Extraction | 16 | 2024 | 467 | 2.340 |
Why?
|
Uveitis, Posterior | 10 | 2020 | 45 | 2.270 |
Why?
|
Vision Disorders | 23 | 2024 | 1088 | 2.190 |
Why?
|
Trachoma | 5 | 2024 | 18 | 1.950 |
Why?
|
Immunosuppressive Agents | 28 | 2023 | 4174 | 1.770 |
Why?
|
Macular Edema | 13 | 2024 | 374 | 1.770 |
Why?
|
Blindness | 12 | 2024 | 584 | 1.610 |
Why?
|
Trichiasis | 2 | 2024 | 4 | 1.590 |
Why?
|
Eye Infections, Viral | 4 | 2023 | 60 | 1.350 |
Why?
|
Eye Diseases | 11 | 2020 | 653 | 1.290 |
Why?
|
Pemphigoid, Benign Mucous Membrane | 8 | 2015 | 113 | 1.190 |
Why?
|
Visually Impaired Persons | 6 | 2024 | 78 | 1.150 |
Why?
|
Glaucoma | 17 | 2023 | 1185 | 1.140 |
Why?
|
Behcet Syndrome | 4 | 2021 | 86 | 1.060 |
Why?
|
Drug Implants | 17 | 2020 | 230 | 1.000 |
Why?
|
Ophthalmology | 7 | 2023 | 550 | 0.990 |
Why?
|
Tuberculosis, Ocular | 5 | 2022 | 8 | 0.980 |
Why?
|
Azathioprine | 3 | 2023 | 354 | 0.920 |
Why?
|
Vitreous Body | 6 | 2020 | 399 | 0.800 |
Why?
|
Prednisolone | 3 | 2017 | 325 | 0.770 |
Why?
|
Acquired Immunodeficiency Syndrome | 9 | 2014 | 2197 | 0.760 |
Why?
|
Retinal Diseases | 4 | 2020 | 704 | 0.760 |
Why?
|
Mycophenolic Acid | 5 | 2023 | 349 | 0.730 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2024 | 354 | 0.730 |
Why?
|
Anti-Inflammatory Agents | 8 | 2019 | 1810 | 0.730 |
Why?
|
Fluprednisolone | 2 | 2017 | 6 | 0.730 |
Why?
|
Antiretroviral Therapy, Highly Active | 14 | 2020 | 1894 | 0.680 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 397 | 0.650 |
Why?
|
Fluorometholone | 1 | 2018 | 4 | 0.640 |
Why?
|
Incidence | 41 | 2024 | 21337 | 0.620 |
Why?
|
Iontophoresis | 1 | 2018 | 74 | 0.610 |
Why?
|
Remission, Spontaneous | 2 | 2016 | 384 | 0.600 |
Why?
|
Triamcinolone Acetonide | 2 | 2018 | 100 | 0.600 |
Why?
|
Intraocular Pressure | 11 | 2020 | 1294 | 0.590 |
Why?
|
Prevalence | 37 | 2024 | 15689 | 0.590 |
Why?
|
Fluorescein Angiography | 9 | 2023 | 1059 | 0.580 |
Why?
|
Retinal Detachment | 7 | 2023 | 428 | 0.570 |
Why?
|
Eye Infections | 3 | 2024 | 62 | 0.570 |
Why?
|
Diabetic Retinopathy | 7 | 2022 | 1273 | 0.540 |
Why?
|
Diagnostic Techniques, Ophthalmological | 4 | 2023 | 251 | 0.520 |
Why?
|
Retrospective Studies | 62 | 2024 | 80566 | 0.490 |
Why?
|
Eye Infections, Bacterial | 4 | 2021 | 242 | 0.480 |
Why?
|
Dexamethasone | 3 | 2023 | 1947 | 0.480 |
Why?
|
Humans | 185 | 2024 | 760617 | 0.460 |
Why?
|
Remission Induction | 2 | 2019 | 2391 | 0.450 |
Why?
|
Vision, Low | 5 | 2018 | 163 | 0.440 |
Why?
|
Ethiopia | 4 | 2024 | 460 | 0.440 |
Why?
|
Developing Countries | 3 | 2019 | 2867 | 0.430 |
Why?
|
Models, Structural | 1 | 2013 | 340 | 0.430 |
Why?
|
Conjunctival Diseases | 4 | 2024 | 110 | 0.430 |
Why?
|
Adult | 94 | 2024 | 220969 | 0.420 |
Why?
|
Follow-Up Studies | 31 | 2024 | 39063 | 0.420 |
Why?
|
Tomography, Optical Coherence | 12 | 2023 | 2916 | 0.410 |
Why?
|
Middle Aged | 88 | 2024 | 220584 | 0.410 |
Why?
|
Ocular Hypotension | 1 | 2012 | 23 | 0.410 |
Why?
|
Male | 108 | 2024 | 360358 | 0.410 |
Why?
|
Risk Factors | 47 | 2023 | 74115 | 0.400 |
Why?
|
Ophthalmia, Sympathetic | 2 | 2023 | 18 | 0.400 |
Why?
|
Retinal Necrosis Syndrome, Acute | 2 | 2023 | 24 | 0.400 |
Why?
|
Female | 110 | 2024 | 392148 | 0.390 |
Why?
|
Refractive Errors | 3 | 2020 | 147 | 0.390 |
Why?
|
Prednisone | 9 | 2019 | 1562 | 0.380 |
Why?
|
Methotrexate | 5 | 2023 | 1716 | 0.370 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2013 | 581 | 0.360 |
Why?
|
Cohort Studies | 25 | 2023 | 41457 | 0.360 |
Why?
|
India | 7 | 2021 | 2286 | 0.350 |
Why?
|
Chorioretinitis | 2 | 2020 | 43 | 0.340 |
Why?
|
Endophthalmitis | 2 | 2010 | 260 | 0.340 |
Why?
|
Macula Lutea | 2 | 2023 | 177 | 0.340 |
Why?
|
Choroidal Neovascularization | 1 | 2013 | 363 | 0.340 |
Why?
|
Anterior Chamber | 4 | 2017 | 194 | 0.320 |
Why?
|
Glaucoma Drainage Implants | 1 | 2010 | 107 | 0.320 |
Why?
|
Treatment Outcome | 31 | 2024 | 64568 | 0.310 |
Why?
|
Publications | 1 | 2011 | 194 | 0.310 |
Why?
|
HIV Infections | 8 | 2020 | 17337 | 0.300 |
Why?
|
Herpes Simplex | 2 | 2023 | 465 | 0.300 |
Why?
|
Phacoemulsification | 3 | 2024 | 149 | 0.300 |
Why?
|
Retinal Vasculitis | 3 | 2020 | 46 | 0.300 |
Why?
|
Adolescent | 41 | 2024 | 88234 | 0.300 |
Why?
|
Macular Degeneration | 7 | 2020 | 1007 | 0.300 |
Why?
|
Epidemiologic Methods | 3 | 2011 | 1335 | 0.290 |
Why?
|
Corneal Ulcer | 2 | 2019 | 128 | 0.290 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2015 | 4341 | 0.280 |
Why?
|
Antimetabolites | 2 | 2023 | 129 | 0.280 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 1400 | 0.280 |
Why?
|
Inflammation | 17 | 2023 | 10760 | 0.280 |
Why?
|
Visual Fields | 6 | 2015 | 1062 | 0.270 |
Why?
|
Antitubercular Agents | 5 | 2022 | 1374 | 0.270 |
Why?
|
Age Distribution | 10 | 2024 | 2871 | 0.270 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2222 | 0.270 |
Why?
|
Neoplasms | 4 | 2023 | 22131 | 0.260 |
Why?
|
Sex Distribution | 8 | 2024 | 2278 | 0.260 |
Why?
|
Artificial Intelligence | 4 | 2024 | 2574 | 0.260 |
Why?
|
Cytomegalovirus Infections | 2 | 2023 | 828 | 0.250 |
Why?
|
CD4 Lymphocyte Count | 10 | 2014 | 2567 | 0.250 |
Why?
|
Cyclosporine | 2 | 2023 | 778 | 0.250 |
Why?
|
Aged | 50 | 2024 | 169042 | 0.250 |
Why?
|
Anti-Retroviral Agents | 2 | 2020 | 1782 | 0.240 |
Why?
|
Uveomeningoencephalitic Syndrome | 2 | 2020 | 22 | 0.240 |
Why?
|
Young Adult | 26 | 2024 | 59179 | 0.240 |
Why?
|
Choroid Diseases | 1 | 2005 | 63 | 0.240 |
Why?
|
Adrenal Cortex Hormones | 2 | 2022 | 1879 | 0.240 |
Why?
|
Environmental Monitoring | 1 | 2011 | 1460 | 0.240 |
Why?
|
Ocular Hypertension | 2 | 2017 | 209 | 0.240 |
Why?
|
Refraction, Ocular | 3 | 2014 | 184 | 0.230 |
Why?
|
Prospective Studies | 22 | 2024 | 54360 | 0.220 |
Why?
|
Immunoglobulin G | 2 | 2013 | 4533 | 0.220 |
Why?
|
Visual Perception | 1 | 2012 | 1388 | 0.220 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2023 | 37 | 0.220 |
Why?
|
Decision Support Techniques | 1 | 2013 | 1998 | 0.210 |
Why?
|
Alkylating Agents | 1 | 2023 | 133 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.210 |
Why?
|
Antibodies, Monoclonal | 4 | 2015 | 9172 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 10754 | 0.200 |
Why?
|
Tissue and Organ Procurement | 2 | 2021 | 962 | 0.200 |
Why?
|
Research Design | 4 | 2011 | 6174 | 0.200 |
Why?
|
Sickness Impact Profile | 4 | 2023 | 299 | 0.200 |
Why?
|
Case-Control Studies | 5 | 2021 | 22148 | 0.200 |
Why?
|
Antiviral Agents | 10 | 2023 | 3039 | 0.190 |
Why?
|
Aged, 80 and over | 24 | 2021 | 58894 | 0.190 |
Why?
|
Double-Blind Method | 5 | 2018 | 12334 | 0.190 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2689 | 0.180 |
Why?
|
Corneal Dystrophies, Hereditary | 1 | 2021 | 64 | 0.180 |
Why?
|
Child | 28 | 2024 | 80079 | 0.180 |
Why?
|
Choroiditis | 1 | 2020 | 12 | 0.180 |
Why?
|
Herpes Zoster | 1 | 2023 | 253 | 0.180 |
Why?
|
Intravitreal Injections | 5 | 2023 | 385 | 0.180 |
Why?
|
Ophthalmic Solutions | 2 | 2019 | 312 | 0.170 |
Why?
|
Corneal Opacity | 2 | 2018 | 47 | 0.170 |
Why?
|
Leprosy | 3 | 2019 | 126 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 2270 | 0.170 |
Why?
|
Toxoplasmosis, Ocular | 1 | 2019 | 29 | 0.170 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 1 | 2021 | 112 | 0.170 |
Why?
|
Lens Implantation, Intraocular | 3 | 2024 | 191 | 0.160 |
Why?
|
Sjogren's Syndrome | 1 | 2021 | 237 | 0.160 |
Why?
|
United States | 24 | 2023 | 72272 | 0.160 |
Why?
|
Neglected Diseases | 1 | 2019 | 66 | 0.160 |
Why?
|
Quality of Life | 8 | 2023 | 13347 | 0.150 |
Why?
|
Tonometry, Ocular | 3 | 2015 | 235 | 0.150 |
Why?
|
Child, Preschool | 14 | 2021 | 42188 | 0.150 |
Why?
|
Ganciclovir | 3 | 2023 | 252 | 0.150 |
Why?
|
Multicenter Studies as Topic | 3 | 2023 | 1700 | 0.140 |
Why?
|
Databases, Factual | 5 | 2018 | 7960 | 0.140 |
Why?
|
Observer Variation | 3 | 2014 | 2606 | 0.140 |
Why?
|
Anterior Eye Segment | 1 | 2018 | 143 | 0.140 |
Why?
|
Administration, Oral | 7 | 2023 | 4010 | 0.140 |
Why?
|
Odds Ratio | 3 | 2014 | 9643 | 0.140 |
Why?
|
Absorptiometry, Photon | 1 | 2023 | 1738 | 0.140 |
Why?
|
Risk Assessment | 10 | 2020 | 23972 | 0.140 |
Why?
|
Leprostatic Agents | 2 | 2006 | 14 | 0.140 |
Why?
|
Eye Infections, Fungal | 1 | 2017 | 100 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2020 | 3514 | 0.130 |
Why?
|
Reproducibility of Results | 10 | 2023 | 20074 | 0.130 |
Why?
|
Immunomodulation | 1 | 2020 | 548 | 0.130 |
Why?
|
Photography | 4 | 2022 | 532 | 0.130 |
Why?
|
Retina | 3 | 2022 | 2655 | 0.120 |
Why?
|
Conjunctivitis | 2 | 2014 | 155 | 0.120 |
Why?
|
Cross-Sectional Studies | 9 | 2020 | 26049 | 0.120 |
Why?
|
Injections, Intraocular | 1 | 2014 | 33 | 0.120 |
Why?
|
HIV | 2 | 2020 | 1579 | 0.120 |
Why?
|
Hormone Replacement Therapy | 1 | 2020 | 750 | 0.120 |
Why?
|
Intraoperative Complications | 1 | 2021 | 1161 | 0.120 |
Why?
|
Keratitis | 1 | 2017 | 241 | 0.110 |
Why?
|
Cytomegalovirus | 3 | 2023 | 749 | 0.110 |
Why?
|
Maryland | 2 | 2005 | 277 | 0.110 |
Why?
|
Necrosis | 1 | 2018 | 1610 | 0.110 |
Why?
|
Infant | 8 | 2021 | 36152 | 0.110 |
Why?
|
Time Factors | 11 | 2020 | 39913 | 0.110 |
Why?
|
Osteoporosis | 1 | 2023 | 1604 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 10199 | 0.110 |
Why?
|
Metformin | 1 | 2021 | 906 | 0.110 |
Why?
|
Recurrence | 6 | 2024 | 8426 | 0.110 |
Why?
|
Viral Load | 4 | 2014 | 3325 | 0.100 |
Why?
|
Retinal Neovascularization | 1 | 2015 | 288 | 0.100 |
Why?
|
Retinal Perforations | 1 | 2014 | 138 | 0.100 |
Why?
|
Postoperative Complications | 3 | 2024 | 15612 | 0.100 |
Why?
|
Filtering Surgery | 2 | 2003 | 33 | 0.100 |
Why?
|
Fluoroquinolones | 1 | 2014 | 306 | 0.100 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2007 | 4366 | 0.100 |
Why?
|
Drug Therapy, Combination | 9 | 2020 | 6305 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2019 | 1389 | 0.090 |
Why?
|
Anti-Infective Agents | 1 | 1999 | 983 | 0.090 |
Why?
|
Forecasting | 1 | 2020 | 2924 | 0.090 |
Why?
|
Aging | 3 | 2017 | 8699 | 0.090 |
Why?
|
Delivery of Health Care | 4 | 2021 | 5332 | 0.090 |
Why?
|
Suppuration | 1 | 2009 | 60 | 0.090 |
Why?
|
Population Surveillance | 1 | 2020 | 2595 | 0.090 |
Why?
|
Cost-Benefit Analysis | 2 | 2014 | 5491 | 0.080 |
Why?
|
Biomedical Research | 2 | 2018 | 3426 | 0.080 |
Why?
|
Capillary Permeability | 1 | 2013 | 773 | 0.080 |
Why?
|
Australia | 3 | 2017 | 1248 | 0.080 |
Why?
|
Data Collection | 1 | 2018 | 3315 | 0.080 |
Why?
|
Optic Nerve Diseases | 1 | 2013 | 342 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2004 | 3415 | 0.080 |
Why?
|
Proportional Hazards Models | 5 | 2021 | 12447 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2756 | 0.080 |
Why?
|
Asia, Southeastern | 2 | 2018 | 114 | 0.080 |
Why?
|
Tuberculosis | 1 | 2021 | 2015 | 0.080 |
Why?
|
Anesthesia, Local | 2 | 2001 | 277 | 0.080 |
Why?
|
Health Surveys | 4 | 2012 | 4037 | 0.080 |
Why?
|
Retinal Vein | 1 | 2008 | 47 | 0.080 |
Why?
|
Clinical Competence | 1 | 2024 | 4789 | 0.080 |
Why?
|
Vitamin D Deficiency | 1 | 2018 | 1388 | 0.080 |
Why?
|
Postoperative Care | 1 | 2015 | 1467 | 0.080 |
Why?
|
Pattern Recognition, Visual | 1 | 1994 | 824 | 0.070 |
Why?
|
Eye | 2 | 2022 | 712 | 0.070 |
Why?
|
Retinal Artery | 1 | 2008 | 109 | 0.070 |
Why?
|
Infant, Newborn | 3 | 2023 | 26180 | 0.070 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5835 | 0.070 |
Why?
|
Sensitivity and Specificity | 4 | 2022 | 14648 | 0.070 |
Why?
|
Retinal Vessels | 1 | 2013 | 852 | 0.070 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2214 | 0.070 |
Why?
|
Optic Disk | 1 | 2011 | 421 | 0.070 |
Why?
|
Perioperative Care | 1 | 2015 | 1037 | 0.070 |
Why?
|
Hepatitis, Autoimmune | 1 | 2009 | 172 | 0.070 |
Why?
|
Europe | 3 | 2018 | 3413 | 0.070 |
Why?
|
Delphi Technique | 2 | 2020 | 846 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3244 | 0.070 |
Why?
|
Indoles | 1 | 2014 | 1830 | 0.070 |
Why?
|
Preoperative Care | 1 | 2015 | 2241 | 0.060 |
Why?
|
Orbital Pseudotumor | 1 | 2005 | 42 | 0.060 |
Why?
|
Anti-HIV Agents | 5 | 2007 | 4524 | 0.060 |
Why?
|
Antirheumatic Agents | 1 | 2015 | 1365 | 0.060 |
Why?
|
Nephritis, Interstitial | 1 | 2006 | 155 | 0.060 |
Why?
|
Cocaine-Related Disorders | 1 | 2008 | 461 | 0.060 |
Why?
|
Retinal Artery Occlusion | 1 | 2005 | 77 | 0.060 |
Why?
|
Cytosine | 1 | 2006 | 211 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1977 | 0.060 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2014 | 2057 | 0.060 |
Why?
|
Chronic Disease | 3 | 2019 | 9311 | 0.060 |
Why?
|
Retinal Vein Occlusion | 1 | 2005 | 149 | 0.060 |
Why?
|
Pseudophakia | 1 | 2004 | 60 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8645 | 0.060 |
Why?
|
Aphakia, Postcataract | 1 | 2004 | 52 | 0.060 |
Why?
|
Silicone Oils | 1 | 2003 | 22 | 0.060 |
Why?
|
Risk | 2 | 2014 | 9604 | 0.060 |
Why?
|
Functional Laterality | 2 | 2005 | 2256 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2009 | 2218 | 0.060 |
Why?
|
HIV Seronegativity | 1 | 2004 | 211 | 0.050 |
Why?
|
Cost of Illness | 2 | 2018 | 1935 | 0.050 |
Why?
|
Radiography, Thoracic | 2 | 2020 | 1302 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2012 | 1375 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6807 | 0.050 |
Why?
|
Anxiety Disorders | 1 | 2014 | 2723 | 0.050 |
Why?
|
Cornea | 1 | 2011 | 1332 | 0.050 |
Why?
|
Disease Management | 2 | 2024 | 2506 | 0.050 |
Why?
|
Morbidity | 1 | 2008 | 1750 | 0.050 |
Why?
|
Injections | 1 | 2006 | 832 | 0.050 |
Why?
|
Rural Population | 2 | 2010 | 2276 | 0.050 |
Why?
|
Aqueous Humor | 1 | 2023 | 153 | 0.050 |
Why?
|
Acyclovir | 1 | 2023 | 267 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6474 | 0.050 |
Why?
|
Herpesvirus 3, Human | 1 | 2023 | 159 | 0.050 |
Why?
|
Arthritis, Reactive | 1 | 2021 | 20 | 0.050 |
Why?
|
Fundus Oculi | 2 | 2004 | 556 | 0.050 |
Why?
|
Consensus | 2 | 2022 | 3117 | 0.050 |
Why?
|
Health Care Costs | 3 | 2014 | 3238 | 0.050 |
Why?
|
Comorbidity | 2 | 2013 | 10505 | 0.050 |
Why?
|
Polymyalgia Rheumatica | 1 | 2021 | 52 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2014 | 1722 | 0.050 |
Why?
|
Tissue Donors | 2 | 2021 | 2331 | 0.050 |
Why?
|
Keratoplasty, Penetrating | 1 | 2021 | 144 | 0.050 |
Why?
|
Neuropsychological Tests | 1 | 1994 | 7050 | 0.050 |
Why?
|
Trabeculectomy | 1 | 2002 | 174 | 0.050 |
Why?
|
Acute Disease | 3 | 2023 | 7237 | 0.040 |
Why?
|
Economics, Pharmaceutical | 1 | 2001 | 87 | 0.040 |
Why?
|
Onchocerciasis, Ocular | 1 | 2019 | 7 | 0.040 |
Why?
|
Epiretinal Membrane | 1 | 2020 | 73 | 0.040 |
Why?
|
Anti-Bacterial Agents | 2 | 2019 | 7402 | 0.040 |
Why?
|
Exudates and Transudates | 1 | 2020 | 174 | 0.040 |
Why?
|
Cause of Death | 2 | 2008 | 3683 | 0.040 |
Why?
|
Spondylitis, Ankylosing | 1 | 2021 | 155 | 0.040 |
Why?
|
Herpesviridae Infections | 1 | 2021 | 269 | 0.040 |
Why?
|
Photometry | 1 | 2019 | 57 | 0.040 |
Why?
|
Simplexvirus | 1 | 2023 | 802 | 0.040 |
Why?
|
Asia, Central | 1 | 2018 | 13 | 0.040 |
Why?
|
Tuberculin Test | 1 | 2020 | 206 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3527 | 0.040 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2021 | 363 | 0.040 |
Why?
|
Measles | 1 | 2021 | 181 | 0.040 |
Why?
|
Oceania | 1 | 2018 | 16 | 0.040 |
Why?
|
Health Status | 1 | 2012 | 4075 | 0.040 |
Why?
|
Africa, Northern | 1 | 2018 | 86 | 0.040 |
Why?
|
Drug Administration Routes | 1 | 2018 | 150 | 0.040 |
Why?
|
Evidence-Based Medicine | 4 | 2003 | 3680 | 0.040 |
Why?
|
Pigment Epithelium of Eye | 1 | 1999 | 209 | 0.040 |
Why?
|
Policy | 1 | 2022 | 506 | 0.040 |
Why?
|
Atrophy | 1 | 2023 | 1631 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 929 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8516 | 0.040 |
Why?
|
Photoreceptor Cells | 1 | 1999 | 235 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5672 | 0.040 |
Why?
|
Middle East | 1 | 2018 | 231 | 0.040 |
Why?
|
Age Factors | 2 | 2012 | 18381 | 0.040 |
Why?
|
Health Status Indicators | 1 | 2003 | 969 | 0.040 |
Why?
|
HIV Protease Inhibitors | 1 | 2000 | 432 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2003 | 861 | 0.040 |
Why?
|
Vitrectomy | 2 | 2015 | 392 | 0.040 |
Why?
|
Prognosis | 3 | 2013 | 29600 | 0.040 |
Why?
|
Glaucoma, Open-Angle | 1 | 2004 | 738 | 0.040 |
Why?
|
Anesthetics, Local | 2 | 2001 | 997 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 745 | 0.040 |
Why?
|
Vasculitis | 1 | 2021 | 522 | 0.030 |
Why?
|
Anesthesia, Conduction | 1 | 2000 | 262 | 0.030 |
Why?
|
Patient Care | 1 | 2022 | 621 | 0.030 |
Why?
|
Giant Cell Arteritis | 1 | 2021 | 306 | 0.030 |
Why?
|
Registries | 2 | 2023 | 8207 | 0.030 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2000 | 621 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 2 | 2023 | 3752 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2005 | 2417 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1504 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 1999 | 13635 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5697 | 0.030 |
Why?
|
Sarcoidosis | 1 | 2021 | 521 | 0.030 |
Why?
|
Lasers | 1 | 2019 | 952 | 0.030 |
Why?
|
Developed Countries | 1 | 2018 | 450 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 612 | 0.030 |
Why?
|
Depression | 1 | 2014 | 8132 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5812 | 0.030 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7389 | 0.030 |
Why?
|
Presbyopia | 1 | 1994 | 10 | 0.030 |
Why?
|
Health Expenditures | 1 | 2007 | 2361 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 1040 | 0.030 |
Why?
|
Disease Progression | 4 | 2004 | 13495 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 1517 | 0.030 |
Why?
|
HLA-B27 Antigen | 1 | 2013 | 63 | 0.030 |
Why?
|
Healthcare Disparities | 1 | 2009 | 3351 | 0.030 |
Why?
|
Insurance Claim Review | 1 | 2018 | 741 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2014 | 310 | 0.030 |
Why?
|
Smoking | 1 | 2010 | 9050 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2023 | 2048 | 0.030 |
Why?
|
Psoriasis | 1 | 2021 | 944 | 0.030 |
Why?
|
Orientation | 1 | 1994 | 321 | 0.030 |
Why?
|
Discrimination Learning | 1 | 1994 | 278 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2014 | 6224 | 0.020 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1086 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2008 | 14591 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2009 | 5430 | 0.020 |
Why?
|
Dacarbazine | 1 | 2014 | 559 | 0.020 |
Why?
|
Myopia | 1 | 1994 | 252 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2017 | 1970 | 0.020 |
Why?
|
Axial Length, Eye | 1 | 2011 | 35 | 0.020 |
Why?
|
Multivariate Analysis | 3 | 2014 | 12043 | 0.020 |
Why?
|
Causality | 2 | 2010 | 1240 | 0.020 |
Why?
|
Immune System | 2 | 2006 | 791 | 0.020 |
Why?
|
Body Weights and Measures | 1 | 2011 | 208 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 617 | 0.020 |
Why?
|
Biological Products | 1 | 2019 | 912 | 0.020 |
Why?
|
Bone Density | 1 | 2023 | 3548 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1865 | 0.020 |
Why?
|
Quality Control | 2 | 2004 | 831 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 30016 | 0.020 |
Why?
|
United States Agency for Healthcare Research and Quality | 1 | 2009 | 85 | 0.020 |
Why?
|
Dry Eye Syndromes | 1 | 2014 | 387 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20556 | 0.020 |
Why?
|
Family | 1 | 2020 | 3193 | 0.020 |
Why?
|
Rural Health | 1 | 2010 | 296 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 590 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2152 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2002 | 7995 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2023 | 12966 | 0.020 |
Why?
|
Eligibility Determination | 1 | 2011 | 421 | 0.020 |
Why?
|
Transportation | 1 | 2009 | 217 | 0.020 |
Why?
|
Health Promotion | 1 | 2019 | 2206 | 0.020 |
Why?
|
Reference Values | 1 | 1994 | 4919 | 0.020 |
Why?
|
Decision Making | 1 | 2020 | 3918 | 0.020 |
Why?
|
Uveal Diseases | 1 | 2006 | 45 | 0.020 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2021 | 2423 | 0.020 |
Why?
|
Logistic Models | 1 | 2021 | 13245 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2011 | 708 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2009 | 429 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4845 | 0.020 |
Why?
|
Indomethacin | 1 | 2006 | 323 | 0.020 |
Why?
|
Recovery of Function | 2 | 2006 | 2978 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 4007 | 0.020 |
Why?
|
Psychomotor Performance | 1 | 1994 | 1882 | 0.020 |
Why?
|
HIV-1 | 1 | 2003 | 6858 | 0.020 |
Why?
|
DNA, Viral | 2 | 2003 | 2195 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2014 | 2191 | 0.020 |
Why?
|
Contrast Sensitivity | 1 | 2007 | 253 | 0.020 |
Why?
|
Bacteriological Techniques | 1 | 2006 | 275 | 0.020 |
Why?
|
Uganda | 1 | 2010 | 1332 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6987 | 0.010 |
Why?
|
China | 1 | 2011 | 2374 | 0.010 |
Why?
|
Prostheses and Implants | 1 | 2011 | 1269 | 0.010 |
Why?
|
Vitamin D | 1 | 2018 | 3302 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2014 | 5463 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2010 | 2700 | 0.010 |
Why?
|
Mitomycin | 1 | 2002 | 263 | 0.010 |
Why?
|
Health Services Research | 1 | 2009 | 1808 | 0.010 |
Why?
|
Urban Population | 1 | 2010 | 2033 | 0.010 |
Why?
|
Laser Coagulation | 1 | 2003 | 330 | 0.010 |
Why?
|
Urine | 1 | 2003 | 362 | 0.010 |
Why?
|
Health Resources | 1 | 2007 | 933 | 0.010 |
Why?
|
Epidemiologic Studies | 1 | 2004 | 673 | 0.010 |
Why?
|
Autonomic Nerve Block | 1 | 2001 | 80 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2013 | 3356 | 0.010 |
Why?
|
Blood | 1 | 2003 | 596 | 0.010 |
Why?
|
Syndrome | 1 | 2006 | 3268 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 14018 | 0.010 |
Why?
|
Hemoglobins | 1 | 2005 | 1524 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2014 | 11116 | 0.010 |
Why?
|
Patient Selection | 1 | 2011 | 4237 | 0.010 |
Why?
|
HIV Reverse Transcriptase | 1 | 2000 | 212 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 3085 | 0.010 |
Why?
|
Software | 1 | 2013 | 4431 | 0.010 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2002 | 645 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2003 | 858 | 0.010 |
Why?
|
Insurance Coverage | 1 | 2009 | 1937 | 0.010 |
Why?
|
Antigens, Viral | 1 | 2002 | 987 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1642 | 0.010 |
Why?
|
Placebos | 1 | 2002 | 1667 | 0.010 |
Why?
|
Orbit | 1 | 2001 | 457 | 0.010 |
Why?
|
Ultrasonography | 1 | 2011 | 5964 | 0.010 |
Why?
|
RNA, Viral | 1 | 2005 | 2838 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2014 | 10175 | 0.010 |
Why?
|
Conscious Sedation | 1 | 2000 | 531 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15828 | 0.010 |
Why?
|
Pain Measurement | 1 | 2001 | 3546 | 0.010 |
Why?
|
Pain, Postoperative | 1 | 2001 | 1737 | 0.010 |
Why?
|
Health Policy | 1 | 2001 | 2682 | 0.000 |
Why?
|